CN Patent

CN104146953A — 一种氢溴酸沃替西汀注射液

Assigned to Individual · Expires 2014-11-19 · 11y expired

What this patent protects

本发明涉及一种氢溴酸沃替西汀注射液，其特征在于由氢溴酸沃替西汀、乙二胺四乙酸或乙二胺四乙酸盐、氯化钠和注射用水组成。本发明制备的氢溴酸沃替西汀注射液提高了氢溴酸沃替西汀溶液的稳定性，制备时可以耐受较高温度充分灭菌而降解产物(杂质)无明显增加，未知单杂均能控制在0.1％以下，大大减小了因降解产物(杂质)增加而给患者用药安全带来的隐患。

USPTO Abstract

本发明涉及一种氢溴酸沃替西汀注射液，其特征在于由氢溴酸沃替西汀、乙二胺四乙酸或乙二胺四乙酸盐、氯化钠和注射用水组成。本发明制备的氢溴酸沃替西汀注射液提高了氢溴酸沃替西汀溶液的稳定性，制备时可以耐受较高温度充分灭菌而降解产物(杂质)无明显增加，未知单杂均能控制在0.1％以下，大大减小了因降解产物(杂质)增加而给患者用药安全带来的隐患。

Drugs covered by this patent

vortioxetine-hydrobromide (VORTIOXETINE HYDROBROMIDE)

Patent Metadata

Patent number: CN104146953A
Jurisdiction: CN
Classification: —
Expires: 2014-11-19
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.